Lilly(Eli) & Co Shares Close in on 52-Week High - Market Mover
The shares closed 1.9% below its 52-week high of $368.77, with trading volume lower than its 30 day average
Nov 23, 2022 by Kwhen Finance Editors
- Trading volume this week was 28.1% lower than the 20-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.6.
- The Relative Strength Index (RSI) on the stock was between 30 and 70.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed below its Bollinger band, indicating it may be oversold.
Fundamentals & Catalysts
- Over the past 12 months the company generated $8 billion in earnings before interest and taxes from $25 billion in revenue. It currently holds $3 billion in cash and $11 billion in debt.
- Its forward price-to-earnings (P/E) ratio of 25.213330185718505 is lower than its current P/E ratio of 56.84, implying that analysts are expecting an increase in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at 2.94. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 6.79 which means it currently has $6.79 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 27.77. This means that the stock is trading at a premium of 28 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 7.52.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 8.03.
Market Comparative Performance
- The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis
- The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis
- The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis
|Name||DoD %Δ||YTD %Δ||1 Yr %||52-Week H %||52-Week L %|
|Lilly(Eli) & Co||0.2||32.4||40.5||-2.0||57.4|
|Dow Jones Industrial Average||0.3||-4.5||-2.4||-6.2||19.1|
|S&P 500 Index||0.6||-14.8||-13.2||-15.8||14.8|
Peer Group Comparative Performance
- The company's stock price performance year-to-date beats the peer average by 232.7%
- The company's stock price performance over the past 12 months beats the peer average by 132.2%
- The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 127.1% higher than the average peer.
|Name||MKT CAP (USD)||P/E||YTD %Δ||1 Yr %Δ||52-Week H %||52-Week L %|
|Lilly(Eli) & Co||LLY||56.8||32.4||40.5||-2.0||57.4|
|Johnson & Johnson||JNJ||24.1||6.1||13.6||-3.6||16.2|
|Merck & Co Inc||MRK||17.8||43.0||35.5||-0.5||54.3|
|Novartis AG - ADR||NVS||9.7||4.5||12.4||-7.3||18.0|
|Astrazeneca plc - ADR||AZN||100.2||16.0||19.5|
|Bristol-Myers Squibb Co.||BMY||25.1||30.4||42.5||-3.2||52.3|
|Sanofi - ADR||SNY||16.2||-6.7||-6.4|
|Glaxosmithkline plc - ADR||GSK||4.4||-35.9||-31.5||-41.0||19.4|
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to email@example.com. © 2021 Kwhen Inc.
Was this content valuable for you?